Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study

Clin Gastroenterol Hepatol. 2024 May;22(5):1127-1129.e2. doi: 10.1016/j.cgh.2023.09.027. Epub 2023 Oct 4.

Abstract

The REMSWITCH study recently demonstrated that switching from intravenous (IV) to subcutaneous (SC) infliximab (IFX) is feasible and well-accepted leading to a low risk of relapse in patients with inflammatory bowel disease (IBD).1 Because the doses of IV IFX depend on patients' weight contrary to SC IFX, whether the switch is also feasible in patients with IBD suffering from obesity remains questionable.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravenous*
  • Adult
  • Drug Substitution / methods
  • Female
  • Gastrointestinal Agents / administration & dosage
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Inflammatory Bowel Diseases* / complications
  • Inflammatory Bowel Diseases* / drug therapy
  • Infliximab* / administration & dosage
  • Infliximab* / therapeutic use
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Obesity* / complications
  • Obesity* / drug therapy
  • Treatment Outcome
  • Young Adult

Substances

  • Infliximab
  • Gastrointestinal Agents